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Abstract
Phosphoinositide 3-kinase (PI3K) phosphorylates phosphatidylinositol 4,5-diphos-
phate to phosphatidylinositol 3,4,5-triphosphate which then activates multiple intra-
cellular signaling proteins such as protein kinase B (Akt), glycogen synthase kinase-3β, 
mammalian target of rapamycin (mTOR), etc. PI3K is involved in the regulation of vas-
cular smooth muscle cell contractility, migration and proliferation – processes crucial 
for the pathogenesis of hypertension, atherosclerosis and restenosis. Increased leptin 
concentration in the metabolic syndrome contributes to the pathogenesis of cardio-
vascular diseases, but the effect of leptin on vascular smooth muscle cells is controver-
sial. We examined the effect of experimentally induced hyperleptinemia on PI3K activ-
ity in the rat aortic media in adult male Wistar rats. Leptin, administered for 10 days in 
increasing dose (from 0.05 to 0.25 mg/kg every 12 hours), increased PI3K activity in the 
aortic media about 5-fold. The effect of leptin was markedly attenuated by epidermal 
growth factor receptor (EGFR) inhibitor, AG1478, as well as by the ErbB2 receptor inhibi-
tor, AG825. In addition, leptin increased tyrosine phosphorylation of ErbB2, which was 
abolished by either AG1478 or AG825. These results indicate that hyperleptinemia in-
creases the activity of vascular ErbB2 receptor in EGFR-dependent manner. In addition, 
both EGFR and ErbB2 contribute to PI3K stimulation by leptin. Activation of ErbB2 and 
PI3K may contribute to detrimental effects of leptin on vascular contractility and re-
modeling and may be involved, at least in part, in the relationship between metabolic 
syndrome and increased risk of vascular restenosis after angioplasty.
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introduction
Phosphoinositide 3-kinases (PI3K) 
constitute the family of lipid kinases 
which phosphorylate hydroxyl group 
at the 3rd position of inositol ring in 
plasma membrane phosphatidylinosi-
tol 4,5-diphosphate (PIP2) converting 
it phosphatidylinositol 3,4,5-triphos-
phate (PIP3). PIP3 regulates the activ-
ity of multiple proteins by binding to 
their pleckstrin homology (PH) do-
mains leading to activation of down-
stream signaling pathway such as 
phosphoinositide-dependent protein 
kinase-1 (PDK-1), protein kinase B 
(Akt), mammalian target of rapamycin 
(mTOR), glycogen synthase kinase-3β 
(GSK-3β) and  ribosomal protein S6 
kinase (S6K). PI3K-dependent sign-
aling is involved in the regulation of 
many physiological processes includ-
ing insulin-induced glucose uptake, 
cell growth, proliferation and sur-
vival (1). In the vascular system, PI3K 
mediates stimulation of endothelial 
NO synthase (eNOS) in endothelial 
cells by various factors such as insu-
lin, estrogens and fluid shear stress, 
whereas in vascular smooth muscle 
cells it is involved in the regulation of 
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and switch between contractile and synthetic/secretory pheno-
types (2). The best characterized class IA PI3Ks are activated by 
growth factor receptors such as epidermal, platelet-derived and 
insulin-like growth factor-1 receptors (EGFR, PDGFR and IGF-
1R). Among them, EGFR is most abundant in the vascular wall 
and is activated therein not only by its multiple ligands but also 
in ligand-independent manner by various mediators such as an-
giotensin II, endothelin 1, thrombin, bradykinin and aldoster-
one (3). Increased EGFR activity contributes to abnormal vaso-
constriction, blood pressure elevation and vascular remodeling 
in various experimental models of hypertension.
Leptin is produced in adipose tissue and regulates energy 
balance by acting on hypothalamic satiety and autonomic cent-
ers. Plasma leptin concentration is markedly increased in obese 
subjects. Many experimental and clinical studies suggest that 
hyperleptinemia is involved in the pathogenesis of cardiovas-
cular complications of obesity including arterial hypertension 
and atherosclerosis (4). Previously, we (5) and others (6) have 
demonstrated that experimentally induced hyperleptinemia ac-
tivates EGFR in the vascular wall in ligand-independent man-
ner; the phenomenon referred to as transactivation. In addition, 
EGFR activated by leptin stimulates downstream extracellular 
signal-regulated kinases (ERK). Apart from ERK, PI3K is the 
second most important signaling pathway triggered by EGFR. 
Although leptin has been demonstrated to stimulate PI3K in 
various tissues (7), its effect on PI3K in the vascular wall has 
not been studied. Although some effects of leptin on vascular 
cells were attenuated by PI3K inhibitors such as wortmannin or 
LY294002, these inhibitors have also PI3K-independent effects 
and thus their effectiveness is not a definite evidence of the in-
volvement of this pathway. Taking into account prominent role 
of PI3K in vascular homeostasis, in the present study we exam-
ined the effect of experimental hyperleptinemia on PI3K activ-
ity in the vascular wall using a recently developed AlphaScreen 
assay. The results indicate that leptin activates PI3K through 




The study was performed on adult male Wistar rats weighing 
237 ± 8 g before the experiment. After 2-week acclimation, ani-
mals were randomized to three experimental groups: (1) con-
trol, (2) leptin-treated, (3) pair-fed, in which the amount of food 
served was restricted to match food intake in leptin-treated 
group (leptin administration decreased food intake by 15-20% 
in this model). Leptin was administered for 10 days in increas-
ing doses from 0.05 to 0.25 mg/kg s.c. twice daily (between 7.00 
and 8.00 AM and between 7.00 and 8.00 PM) to reproduce pro-
gressive increase in plasma leptin observed in the metabolic 
syndrome. The details of the procedure were described previ-
ously (5). Groups not receiving leptin were injected with the 
equal volume of saline. Separate groups of rats received leptin or 
saline plus one of growth factor receptor inhibitors (each once 
daily i.p. in 0.2 ml of 20% DMSO in 0.9% NaCl): AG1478 (EGFR 
inhibitor), AG43 (EGFR-inactive analogue of AG1478), AG825 
(ErbB2 inhibitor), AG1295 (PDGFR inhibitor) or AG1024 (IGF-
1R inhibitor). AG825 was administered at 100 mg/kg/day and all 
other inhibitors at 20 mg/kg/day.
Animals were anesthetized with thiopental (50 mg/kg i.p.) 
6 hours after the last injection and blood was withdrawn from 
the abdominal aorta into EDTA-containing tubes to measure 
plasma leptin, insulin, glucose and lipids. Then, thoracic and ab-
dominal aorta was excised, adventitia and perivascular adipose 
tissue were dissected and endothelium was removed by a cotton 




PI3K activity was measured by a recently developed Alpha 
Screen method (Amplified luminescence proximity homoge-
neous assay). In brief, the method is based on the chain in-
teraction between donor microbeds coated with streptaividin, 
biotinylated PI(1,3,4,5)P4, phosphoinositide detector protein 
(PH domain of mouse general receptor for phosphoinositides, 
GRPI) tagged with glutathione S-transferase (GST), and ac-
ceptor microbeds coated with anti-GST antibody. When this 
interaction occurs, donor microbeds excited with laser light 
(680 nm) produce singlet oxygen (1O2) which induces lumi-
nescence (520-620 nm) in the acceptor beds; the emitted light 
is then detected. PIP3 standard or PIP3 produced by PI3K con-
tained in the sample competes with biotinylated PIP4 for bind-
ing with GRPI and “breaks” the chain interaction between do-
nor and acceptor beds; due to short half-life of singlet oxygen 
(4 μs) it spontaneously returns to basal low-energy state before 
reaching acceptor beds and luminescence signal is not emitted. 
Thus, signal intensity decreases with increasing PIP3 concen-
tration in the sample.
The assay was performed using PI3K assay kit purchased 
from Echelon Bioscience Technology (Salt Lake City, USA), 
suspension of donor and acceptor microbeds was obtained 
from Perkin Elmer GST Alpha Screen Assay kit. Thawed tissue 
samples were homogenized in 10 volumes of 20 mM Tris (pH 
7.5) containing 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% 
Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM Na3VO4, 
1 μg/ml leupeptin and 1 mM phenylmethylsulphone fluoride, 
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results
Characteristics of experimental groups
Final body weight, plasma glucose, triglycerides, total and HDL-
cholesterol did not differ between groups. Leptin concentration 
was markedly higher in leptin-treated group, but was reduced 
by >40% in the pair-fed group in comparison to control. Leptin 
administration had no effect on plasma insulin concentration, 
whereas pair-feeding induced slight decrease in fasting plasma 
insulin suggesting improvement of insulin sensitivity (Tab. 1).
PI3K activity
Leptin administration resulted in about 5-fold elevation of PI3K 
activity in the aortic media. In contrast, pair-feeding had no ef-
fect on PI3K activity (Fig. 1). These results indicate that leptin 
excess but not caloric restriction is responsible for PI3K activa-
tion in leptin-treated group.
and centrifuged at 15 000 × g for 10 min at 4oC. The reaction 
mixture (10 μl) contained 5 μg of tissue supernatant protein, 
10 μM ATP, 5 μM substrate (dioctanoyl-PI(4,5)P2) and 2.5 mM 
MgCl2 in 5 mM HEPES (pH 7.4). After 2 hours at 37
oC, 5 μl of 
50 nM biotinylated PIP4, 5 μl of 1.85 μg/ml detector protein 
(both in 10 mM Tris containing 150 mM NaCl, 7.5 mM EDTA, 
0.1% Tween-20 and 1 mM dithiotreitol, pH 7.4) and 5 μl of 
suspended donor and acceptor microbeds (100 μg/ml each) 
were added to the wells and the plate was incubated for addi-
tional 2 hours at room temperature. The signal was read using 
PherAstar FS (BMG Labtech) microplate reader in the Alpha 
Screen mode (excitation 300 ms, emission 700 ms). Standard 
curve was obtained by adding 10 μl of 0-2,5 μM dioctanoyl-
PIP3 instead of reaction mixture, followed by biotinylated PIP4, 
detector protein and microbeds as described above. PI3K ac-
tivity is expressed in pmol of PIP3 produced per mg of super-
natant protein per hour.
Phosphorylation of ErbB2 receptor
The activity of ErbB2 receptor was assessed by measuring its 
phosphorylation at Tyr1221 and/or Tyr1222 (the major autophos-
phorylation sites for ErbB2 tyrosine kinase and PI3K docking 
site) and global phosphorylation (phosphotyrosine residues re-
gardless of position in the aminoacid chain). These assays were 
performed by ELISA method using kits from Cell Signaling 
Technology. Total ErbB2 level was also measured. In brief, 100 
μl of tissue supernatant used for PI3K assay (diluted to 0.1 mg 
protein/ml) was pipetted to the microplate wells coated with 
anti-ErbB2 antibody. After 2-hour incubation and washing, 100 
μl of secondary antibody solution specific for ErbB2 regardless 
of its phosphorylation state (total ErbB2), ErbB2 phosphoryl-
ated at Tyr1221 and/or Tyr1222, or anti-phosphotyrosine antibod-
ies was added. After 1-hour incubation and washing, horse-
radish-peroxidase-linked antibodies specific for Fc fragment of 
the respective secondary antibodies were added together with 
H2O2+trimethylbenzidine substrate. The results are expressed as 
the ratio between optical density (OD) measured at 450 nm for 
phosphorylated and total ErbB2.
Reagents
Recombinant rat leptin was purchased from R&D Systems. 
AG825 was from Sigma-Aldrich and all other receptor tyrosine 
kinase inhibitors were from Calbiochem.
Statistical analysis
Results are expressed as mean ± SEM from 8 experiments in 
each group. Statistical significance was evaluated by ANOVA 
and Tukey’s post-hoc test. P<0.05 was considered significant.
Figure 1. Phosphoinsitide 3-kinase (PI3K) activity in the aor-
tic media (pmol/mg protein/hour). ***p<0.001 versus control 
group.
Effect of growth factor receptor inhibitors on leptin-induced 
PI3K activation
Because PI3K is activated by growth factor receptors, in subse-
quent studies we examined if and which of these receptors are 
involved in leptin-induced PI3K stimulation. Both AG1478 and 
AG825 reduced this activity in leptin-treated animals, however, 
neither of them completely restored PI3K activity to control 
level. AG1295 reduced PI3K activity in leptin-treated group to 
a much lesser extent (-22.2%). An inactive analogue of AG1478, 
AG43, as well as IGF-1R inhibitor, AG1024, had no effect. 
Neither of tyrphostins had any effect on PI3K in rats not receiv-
ing leptin (Fig. 2). These results indicate that EGFR and ErbB2 
are mostly involved in leptin-induced stimulation of PI3K.
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ErbB2 phosphorylation
Neither leptin nor any of growth factor receptor inhibitors had 
any significant effect on total ErbB2 concentration in the aor-
tic wall (not shown). ErbB2 phosphorylation at Tyr1221/Tyr1222 
was 3-fold higher in leptin-treated that in control animals. Both 
AG1478 and AG825 restored ErbB2 phosphorylation at Tyr1221/
Tyr1222 to the control level, whereas AG1295, AG1024 and AG43 
had no effect. Interestingly, AG1478 and AG825 slightly reduced 
ErbB2 phosphorylation (by 40.7% and 27.0%, respectively) in 
animals not receiving leptin (Fig. 3A).
Leptin induced also marked increase in global ErbB2 phos-
phorylation (total amount of phosphotyrosine residues). This 
effect was partially attenuated but not completely normalized 
by either AG1478 or AG825. AG43, AG1295 and AG1024 had 
no effect on global ErbB2 phosphorylation in leptin-treated ani-
mals. AG1478 reduced global ErbB2 phosphorylation in anmi-
mals not receiving leptin by 46.2%, whereas other inhibitors had 
no effect in this group (Fig. 3B).
discussion
The major finding of this study is that experimental hyperlep-
tinemia induced in lean rats stimulates PI3K in the aortic me-
dia in which vascular smooth muscle cells constitute the main 
cellular component. Hyperleptinemia induced in lean animals 
by administration of exogenous hormone is a good model to 
dissect effects of leptin excess from other endocrine/metabolic 
abnormalities observed in the metabolic syndrome, and thus to 
recognize which detrimental consequences of obesity may be 
Figure 3. Phosphorylation of ErbB2 at Tyr1221/Tyr1222 (A) and global phosphorylation of ErbB2 (the amount of all phosphotyrosine 
residues, B) in rats receiving leptin and/or growth factor receptor inhibitors. Results are expressed as the ratio between optical 
density measured using antibodies specific for phosphorylated ErbB2 and total ErbB2. *p<0.05, ***p<0.001 versus control group; 
###p<0.001 versus group receiving leptin alone.
Figure 2. Effect of growth factor receptor inhibitors on leptin-induced PI3K stimulation in the aortic media. **p<0.01, ***p<0.001 
versus control group; ###p<0.001 versus group receiving leptin alone.
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attributed to hyperleptinemia. Although conditions used dur-
ing PI3K assay such as substrate and ATP concentration, buffer 
composition, etc, are optimal for class IA PI3Ks which are acti-
vated by growth factor receptors, we cannot definitely conclude 
which specific PI3K isoform is activated. Previously, we have 
demonstrated that hyperleptinemia increases EGFR activity in 
the vascular wall by inducing reactive oxygen species-mediated 
stimulation of non-receptor tyrosine kinase c-Src which phos-
phorylates the intracellular domain of EGFR (5). In addition, 
leptin increased ERK activity in EGFR-dependent but IGF-1R 
and PDGFR-independent manner (5,6). Consistently with 
these findings, leptin-induced PI3K stimulation in the present 
study was markedly attenuated by EGFR inhibitor, AG1478. 
Surprisingly, the effect of leptin on PI3K was also markedly re-
versed by ErbB2 inhibitor, AG825. Among all ErbB receptors 
(EGFR/ErbB1 through ErbB4), ErbB2 has no specific ligand but 
may heterodimerize with and be phosphorylated by other ErbB 
family members including EGFR. Indeed, ErbB2 is a preferred 
dimerization partner for other ErbB receptors; binding with 
ErbB2 increases ligand affinity of EGFR, augments its ability to 
stimulate downstream signaling, and prolongs EGFR activation 
by slowing its endocytosis (3,8, 9). Thus the most likely explana-
tion of our findings is that EGFR, activated by leptin, phospho-
rylates and activates ErbB2 which finally recruits the regulatory 
subunit of PI3K leading to its stimulation. Indeed, we demon-
strated that leptin increased ErbB2 phosphorylation in the aor-
tic wall while having no effect on total ErbB2 level, and that its 
effect on ErbB2 phosphorylation was abolished by AG1478 (Fig. 
3), as well as by either antioxidant apocynin or c-Src inhibitor 
PP2 (data not shown), which also abolish the effect of leptin on 
EGFR (5).
Overexpression or constitutive activation of ErbB2 is ob-
served in many cases of human cancer. Previously, leptin has 
been demonstrated to activate ErbB2 in two breast cancer cell 
lines (10) and in human embryonic kidney HEK293T cells 
transfected with ErbB2 (11). In addition, similarly to the present 
study, in SKBR3 breast cancer cells the effect of leptin on ErbB2 
phosphorylation was partially attenuated by AG1478 suggest-
ing the involvement of EGFR (10). Leptin-induced ERK acti-
vation and proliferation of breast cancer cells were attenuated 
by AG825 indicating that ErbB2, stimulated by leptin, is able to 
activate downstream signaling mechanisms. To our knowledge, 
the present study is the first one in which the effect of leptin on 
ErbB2 phosphorylation was demonstrated in nonmalignant tis-
sues.
ErbB2 is expressed in vascular smooth muscle cells but, in 
contrast to EGFR, its role in these cells is poorly understood. It 
has been demonstrated that EGFR/ErbB1 agonist, betacellulin, 
is synthesized by rat aortic smooth muscle cells and stimulates 
phosphorylation of both EGFR and ErbB2; phosphorylation 
of the latter was abolished by EGFR inhibitors confirming that 
both receptors may dimerize in vascular smooth muscle cells 
and that ErbB2 is phosphorylated by liganded EGFR (12). In ad-
dition, betacellulin stimulated smooth muscle cell growth, mi-
gration and proliferation in EGFR, ErbB2, and partially PI3K-
dependent manner (12). Other EGFR ligands such as heparin-
binding EGF-like growth factor, epiregulin and amphiregulin 
are also synthesized in vascular smooth muscle cells and regu-
late their growth and proliferation. Angiotenisn II, thrombin 
and endothelin-1 stimulate synthesis of these ligands and also 
transactivate EGFR in ligand-independent manner (3). Taken 
together, these data indicate that EGFR, either activated by its 
ligands or stimulated in ligand-independent (e.g. transactivated 
by leptin) manner, can phosphorylate ErbB2 and trigger down-
stream signaling pathways including PI3K in vascular smooth 
muscle cells. It should be noted that once phosphorylated, intra-
cellular domain of ErbB2 recruits and activates some signaling 
proteins with greater affinity than EGFR, and specific signaling 
proteins such as FGR, Abl-1 and Syk cytosolic protein tyrosine 
kinases are activated exclusively by ErbB2 but not by EGFR (13). 
The role of ErbB2 in vascular smooth muscle cells needs to be 
studied in more detail in the future.
Functional implications of leptin-induced PI3K stimula-
tion in the vascular wall remain to be established. In contrast 
to endothelial cells where PI3K activates eNOS, PI3K in vascu-
lar smooth muscle cells is rather involved in vasoconstriction. 
Indeed, PI3K is activated by angiotensin II or endothelin-1 
and mediates vasoconstriction by increasing intracellular Ca2+ 
concentration and/or the sensitivity of intracellular contrac-
tile apparatus to Ca2+ (14-18). Increased expression/activity of 
PI3K was observed in experimental models of hypertension 
(19, 20). In addition, genetic or pharmacological PI3K inhibi-
ton reduce blood pressure in experimental animals (21,22). 
Hyperleptinemia is involved in the pathogenesis of hypertension 
in patients with metabolic syndrome (4), thus leptin-induced 
PI3K stimulation in the vascular wall may also contribute to va-
soconstriction. In addition, PI3K and its downstream effectors 
such as Akt, mTOR and S6K are involved in vascular smooth 
muscle cell growth, migration and proliferation; processes cru-
cial for progression of atherosclerosis and restenosis after coro-
nary angioplasty (23-25). Administration of exogenous leptin 
augments, whereas deficiency of leptin or its receptor attenuates 
experimental restenosis induced by vascular injury in rodents 
(26-28), and hyperleptinemia correlates with increased risk of 
restenosis in humans (29-30). However, detrimental effect of 
leptin in the vascular wall is not unequivocal since leptin has 
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been demonstrated to stimulate inducible NO synthase in PI3K-
dependent manner in vascular smooth muscle cells, and to in-
hibit angiotensin II-induced vasoconstriction (31) and smooth 
muscle cell proliferation (32) through the mechanism involving 
PI3K, Akt and iNOS.
In conclusion, we demonstrated that hyperleptinemia in-
duced by administration of exogenous leptin increases PI3K ac-
tivity in the aortic media in EGFR and ErbB2-dependent man-
ner. In addition, leptin activates ErB2 receptor in the vascular 
wall by stimulating its phosphorylation by EGFR. EGFR/ErbB2/
PI3K pathway may contribute to effects of leptin on smooth 
muscle cell contractility, growth and proliferation and may me-
diate, at least in part, the relationship between leptin and cardio-
vascular pathologies in the metabolic syndrome.
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